A Single-Center, Randomized, Double-Blind, Active, and Placebo-Controlled Study of KAI-1678, a Novel PKC-Epsilon Inhibitor, in the Treatment of Acute Postoperative Orthopedic Pain

Abstract

Brief summary of article: Nociceptive properties of protein kinase C (PKC) has been studied for nearly two decades. We found that KAI-1678-a novel inhibitor of epsilon PKC-was not an analgesic for patients with postoperative pain following total hip or total knee replacement surgery. However, a different PKC inhibitor may prove to be a safe and effective analgesic. AbstractObjective. KAI-1678, a novel inhibitor of the interaction of the epsilon isoform of protein kinase C (ePKC) with its intracellular receptor, has demonstrated activity in countering hyperalgesia in several models of pain. In this controlled randomized trial, KAI-1678 was tested for analgesic activity in an orthopedic acute postoperative pain setting.Design. Following hip or knee replacement surgery, subjects were treated with KAI-1678, ketorolac, or saline. Subjects recorded their pain intensity on a visual analog scale and rated their quality of analgesia. The pain intensity differences between baseline and the evaluations were summed over the first 4 hours.Results. The analysis revealed that, while ketorolac displayed good analgesic activity, KAI-1678 was not significantly different than placebo. Analgesia quality ratings similarly did not show a difference between KAI-1678 and placebo in this pain model. A small excess of infusion site erythema was seen with KAI-1678, but otherwise the drug was safe and well tolerated.Conclusions. We investigated the safety and efficacy of a novel inhibitor of ePKC and provide clinical evidence that inhibition of ePKC with KAI-1678 is not effective in the treatment of acute postoperative orthopedic pain.

PKCϵ Is an Essential Mediator of Prostate Cancer Bone Metastasis

“…These findings may have significant therapeutic implications, as PKCε inhibitors with as anti-cancer activity have been generated in the last years, and some are well tolerated in humans (12, 48, 49). It is also worth noting that PKCs have been implicated in osteoclast formation, and recent studies highlighted a potential therapeutic use of pharmacological blockade of PKC-dependent pathways in osteolytic diseases.…”

Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease

“…However, the δV1-1 peptide did not show any significant effect in phase II trials in humans (Lincoff et al, 2014). A similar peptide derived from the C2 domain of PKCε, εV1–2 (aa 14–21, KAI-1678), has a 100-fold selectivity for PKCε over other enzymes and showed efficacy in animal models for prevention of heart failure (Inagaki, Koyanagi, Berry, Sun, & Mochly-Rosen, 2008) and for the inhibition of inflammatory pain (Sweitzer et al, 2004), but again did not show any significant effect in human clinical trials (Cousins, Pickthorn, Huang, Critchley, & Bell, 2013; Moodie, Bisley, Huang, Pickthorn, & Bell, 2013). …”

Protein Kinase C and its Inhibitors in the Regulation of Inflammation: Inducible Nitric Oxide Synthase as an Example

“…The selective PKCδ RACK peptide antagonist KAI‐9803 has been studied for the prevention of reperfusion injury in patients undergoing angioplasty after acute myocardial infarction . PKCε inhibitor KAI‐1678 had no therapeutic effect in the treatment of post‐herpetic neuralgia or post‐operative orthopaedic pain in phase II clinical trials . Bryostatin 1, a macrocyclic lactone, has been studied for the treatment of non‐Hodgkin's lymphoma.…”